ARID1A and neoplasm: The loss of the tumor-suppressor gene AT-rich interaction domain A (ARID1A), a multidrug resistance-associated protein 2 (MRP2) regulator, has been shown to lead to a platinum-resistant phenotype in a preclinical tumor model [19,20,21].